HIV-1 Proviral Sequence and Treatment Outcome of Virologically Suppressed Patients Switching to Coformulated Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate

J Acquir Immune Defic Syndr. 2018 Sep 1;79(1):e45-e51. doi: 10.1097/QAI.0000000000001757.
No abstract available

Publication types

  • Letter

MeSH terms

  • Anti-HIV Agents / therapeutic use*
  • Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination / therapeutic use
  • HIV Infections / drug therapy*
  • HIV Infections / virology
  • HIV-1 / genetics*
  • HIV-1 / isolation & purification
  • Humans
  • Pilot Projects
  • Proviruses / genetics*
  • Proviruses / isolation & purification
  • Treatment Outcome
  • Viral Load*

Substances

  • Anti-HIV Agents
  • Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination